Table 1.
Baseline parameters of the sixty one COVID-19 critically ill patients who received tocilizumab.
| Parameters | Median (IQR)/count (%) | 95% CI |
|---|---|---|
| Age (years) | 51 (42.5–58.75) | 46–54.5 |
| Gender (Male) | 54 (88.2%) | 77.4%–95% |
| Ethnicity (Middle Eastern) | 16 (26.2%) | 15.8%–39% |
| Onset of symptoms to ICU admission (days) | 5 (3.75–6) | 4–6 |
| SpO2/FiO2 ratio | 162 (145–209.2) | 152–191.4 |
| Hemoglobin (g/L, normal: 12–17) | 13.2 (11.5–14.4) | 11.9–13.7 |
| White blood cells (cells/mm3, normal: 4–10) | 8.27 (6.9–9.4) | 7.1–9.1 |
| Platelets (cells/mm3, normal: 150–450) | 277 (187–353) | 192–339 |
| Lymphocyte count (109/L, normal: 1.1–3.2) | 0.8 (0.65–0.92) | 0.72–0.88 |
| C-reactive protein (mg/L, normal: 0–5) | 31.7 (30.5–49.9) | 34.8–42.7 |
| Creatinine (mg/dL, normal: 0.6–1.2) | 0.8 (0.6–1.1) | 0.7–0.9 |
| D-dimers (mcg/ml, normal: < 1) | 2.4 (1.2–3.9) | 1.7–3.1 |
| Pulmonary embolism | 7 (11.4%) | – |
| APACHE 4 score upon ICU admission | 53 (37.75–72.5) | 44.4–63.2 |
| Comorbidities | ||
| More than one comorbidity | 38 (62.3%) | 49%–74.4% |
| Diabetes mellitus | 24 (39.3%) | 27%–52.6% |
| Arterial hypertension | 13 (21.7%) | 12.2%–34.1% |
| Hypothyroidism | 1 (1.6%) | 0.04%–8.7% |
| Obesity (body mass index > 30) | 15 (24.6%) | 14.5%–37.3% |
| Active smoking status | 37 (60.7%) | 47.4%–73% |
| Mechanically ventilated | 29 (47.5%) | – |
| Non-mechanically ventilated | 32 (52.5%) | – |
| ICU length of stay (days) | 13 (9–17) | 11–15 |
| Hospital length of stay (days) | 14 (9–21) | 11–19 |
Abbreviations: IQR = interquartile range, CI = confidence interval, ICU = intensive care unit, SpO2/FiO2 ratio APACHE 4 score = Acute Physiology and Chronic Health Evaluation score.